Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
6.25
-0.16 (-2.50%)
At close: Oct 9, 2026, 4:00 PM EDT
6.25
0.00 (-0.06%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Evommune Revenue
Evommune had revenue of $10.00M in the twelve months ending June 30, 2026, up 233.33% year-over-year. In the year 2025, Evommune had annual revenue of $13.00M with 85.71% growth. That makes Evommune the 37,331st largest company in the world by revenue and 4,902nd in the United States.
Revenue (ttm)
$10.00M
Revenue Growth
+233.33%
P/S Ratio
22.68
Revenue / Employee
$208,333
Employees
48
Market Cap
226.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.00M | 6.00M | 85.71% |
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
EVMN News
- 10 days ago - Evommune presents Phase 2a PoC data on EVO301 at EADV Congress - TheFly
- 10 days ago - Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Business Wire
- 18 days ago - Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Business Wire
- 26 days ago - Evommune Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 26 days ago - Evommune Slides: Corporate presentation - Filings
- 4 weeks ago - Evommune price target lowered to $23 from $28 at Clear Street - TheFly
- 4 weeks ago - Evommune price target lowered to $18 from $32 at Raymond James - TheFly
- 4 weeks ago - Evommune price target lowered to $22 from $28 at Leerink - TheFly